Company "Photonics", Invested Venture Fund and , created with the participation capital of JSC "RVC", received in Roszdravnadzor registration certificate for his first instrument — a laser module stLase for soft tissue surgery.
Ltd. "Photonics" — Private innovation company, founded in 2010 — is engaged in the development and breeding of the domestic market for new medical laser systems for surgery of soft (stLase) And hard tissues (atLase). Advantages of new laser systems are to their compactness, multi-functionality, ergonomics, and the relatively low cost. The main application of stLase — dentistry, but the device can also be used in non-contact cardio-vascular surgery, surgical interventions in obstetrics and gynecology, otorhinolaryngology, proctology and other areas of medicine.In the past year have been completed pre-clinical and clinical studies laser system stLase, which demonstrated the feasibility of key technologies: proven effect on tissue coagulation stLase, achieved with the use of laser-induced thermal radiation and an automatic laser power control, allowing for the first time to produce soft tissue surgery with a new level efficacy and safety, as well as open a new opto-thermo-acoustic effect stLase, which can be used in dentistry to remove tartar in a generation mode of the shock waves and cavitation.
Currently implemented pilot episode 5 devices and developed a plan to promote laser systems to the Russian market. One of the devices already installed in the dental clinic number 49 of the Department of Health of the city of Moscow.
Dmitry Popov, managing partner of venture capital fund "Maxwell Biotech": "We are very pleased that our investment fund led to the emergence of the Russian market of the laser system with unique technological characteristics to solve many health problems."
Alexei Teleshev, Director of RVC Seed Fund: "Laser systems used in dentistry in many countries for their future and Russian dentistry, particularly in surgery. Projects in the field of medicine has always been and remains one of the most complex and interesting, they are quite a long way from idea to market. Photonics company has successfully overcome this way, and we will be glad to support it in the future. "
Igor Shugaylo, MD, Professor, Head of the Department of Dentistry of the Russian Medical Academy of Postgraduate Studies, Chairman of the Russian Association of Laser Dentistry: "In clinical trials stLase leading dentists Russia and the U.S. have seen the benefits of this device, and its implementation in daily practice physicians will significantly improve the quality of the surgical procedures in dentistry."
*
Preclinical studies stLase, conducted in early 2011, have demonstrated the feasibility of the key technologies underlying the new device: proven effect on tissue coagulation stLase, achieved with the use of laser-induced thermal radiation and an automatic laser power control, allowing for the first time to produce soft tissue surgery a new level of efficiency and safety. Compared with existing devices, stLase demonstrates significantly greater efficacy of laser dissection with more optimal level of coagulation that minimize the healing without scarring. A new thermo-opto-acoustic effect with stLase. Studies of this effect has been demonstrated to remove plaque in the mode of generation of the shock waves and cavitation due to thermo-opto-acoustic effect. This effect is supposed to be used for the treatment of periodontal disease in combination with LPM-technology.
Demonstrated by the preliminary results of the first phase of clinical trials of a new method of treatment of periodontal disease based on the regeneration of the gums using technology LPM and stLase. They were significantly better than targets: reducing the depth achieved pathological tooth-gingival pockets of 1 mm in the areas treated with the technology LPM. The same technology is allowed to open and for the first time to be tested in clinical practice a new method for highly efficient and safe treatment of hyperpigmentation gums.
Thus, the study confirmed that stLase can reach the level of CO surgery2 laser (the "gold standard" in today's surgery), but in the contact mode and a much lower cost device. Successful initial tests on the use of stLase for basic procedures in dentistry dentists allowed the leading U.S. and Russia confirm stLase advantages over existing laser systems.
Igor Shugaylo, MD, Professor, Head of the Department of Dentistry of the Russian Medical Academy of Postgraduate Studies, Chairman of the Russian Association of Laser Dentistry "The developers managed to implement one of the most important requirements for surgical laser technology — increase the ablation rate along with a reduction of thermal tissue damage. This was achieved by first implemented the automatic control system of the radiation parameters, unique thermo-optical and opto-thermo-acoustic nibs. stLase — a unique, compact, high-power laser, by which Not only conducted existing, but new technologies are developed operational procedures on the soft tissues of the maxillofacial region. "
Kenneth S. Magid, a doctor of dental surgery, associate professor and director of the School of Dentistry laser program at New York University (New York, USA): "stLase — this is the first laser that allows the procedure to the level of speed, precision and control are not currently achievable with existing diode lasers. "
Review of recognized industry leaders proves that stLase rightly positioned as a premium product with cutting ability, identical lasers, CO2, and higher than the competition, performance monitoring settings and ergonomics. Over the coming months, the work of these and other professionals will continue, in order to optimize clinical protocols stLase and create a best-in-class training program to prepare the product for market. Preliminary results from the last time, the project has already attracted the interest of the two largest companies in the production of dental equipment.
With regard to progress in the development of other laser system — atLase, designed for hard tissue surgery — that in laboratory tests carried out on samples of the device, "Photonics" first investigated the impact of the prototype atLase on hard tissues and established the possibility of texturing and keramizatsii (sintering) of the surface of tooth enamel and dentin to fully protect teeth from decay.
*
About "Photonics"
Ltd. "Photonics" — Russian innovative company, established in 2010. The company is a biotechnology holding "Maxwell Biotech Group", is a resident of the Biomedical Cluster innovation center "Skolkovo" and a member of the Technology Platform "Medicine of the Future." The company is engaged in the development and breeding of the domestic market for new medical laser systems for surgery of soft and hard tissues and works in close partnership with international companies «Dental Photonics» and «Laser Abrasive Technologies», as well as leading Russian institutes and organizations: St. Petersburg State University Information Technologies, Mechanics and Optics (Mechanics and Optics), St. Petersburg State Medical University named after Ivan Pavlov, the Russian Medical Academy of th
e Ministry of Health of Russia, Nizhny Novgorod Medical Academy of Laser Dentistry and the Association of Russia.
About "Maxwell Biotech Group"
— A group of developers and service companies specializing in the development of innovative biotech projects. The company has attracted funding and engaged in the development and market introduction of innovative products and technologies, and actively participates in building an effective infrastructure for the development of innovative companies, using long-term experience of an international team of managers and experts, and best management practices. To date, the assets of seven biotechnology projects: companies' OncoMax "," Photonics "," MetaMax "," Infekteks "," NeyroMaks "," KardioNova "and" Gepatera. " All group companies are among the residents of the Biomedical cluster innovation center "Skolkovo", 5 of them are members of the Technology Platform "Medicine of the Future."
About RVC Seed Fund
set of "RVC" in conjunction with the Foundation for Assistance to Small Innovative Enterprises in the scientific and technical sphere. The Fund is focused on investments in the Russian innovative companies with high growth potential in the domestic and foreign innovation and technology markets. One of the main objectives of the fund is to significantly increase the quantity and quality of small technology businesses, claiming later to receive investments of venture investors and fund early stage. The authorized capital of LLC "RVC Seed Fund" is 2 billion.
For more information, please contact:
Anna Zelenkova, Director of Public Relations, LLC "Maxwell Biotech Group"
Tel: +7 (495) 411-6992
E-mail: